Oracle shares surged last week after the company reported better-than-expected earnings and projected robust growth in its cloud infrastructure revenue. CEO Safra Catz attributed the strong ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug, amycretin, by early 2026. The drug mimics ...

(RTTNews) - Novo Nordisk (NVO) announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. This decision was ...

Novo Nordisk has announced plans to initiate late-stage trials for its amycretin injection and oral drugs targeting adults ...

Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical ...